Pomerantz Law Firm Alerts Pacira Biosciences Investors About Class Action Lawsuit and Critical Deadlines

Pomerantz Law Firm Notifies Pacira Biosciences Investors of Important Class Action Lawsuit

Pomerantz LLP, a well-regarded firm specializing in corporate, securities, and antitrust class litigation, has announced a crucial class action lawsuit against Pacira Biosciences, Inc. (NASDAQ: PCRX). This comes as investors who have suffered losses from their investments in Pacira are being informed about their potential rights and actions they can take.

The lawsuit raises serious concerns regarding whether Pacira and some of its key officers or directors engaged in securities fraud or other questionable business practices. This is particularly pertinent as the firm highlights the importance of contacting them promptly if one has been affected by the company’s recent activities.

Key Details of the Lawsuit

Investors are encouraged to reach out to Danielle Peyton at Pomerantz LLP via email at [email protected] or call 646-581-9980. Alternatively, investors can use the toll-free number 888.4-POMLAW (Ext. 7980) for inquiries. It’s recommended that affected investors provide their mailing addresses, contact numbers, and details of their shares purchased when reaching out.

The deadline for investors to request a lead plaintiff position in this class action is March 14, 2025. This step is significant for individuals who purchased or acquired shares in Pacira during the specified class period. The lawsuit also highlights a troubling incident on August 9, 2024, when the U.S. District Court for the District of New Jersey invalidated Pacira's '495 patent related to its Exparel non-opioid pain treatment, deeming it obvious and anticipated. Following this announcement, Pacira's shares plummeted by $10.66 (about 47.67%), closing at $11.70. This severe drop in stock price has prompted the need for such a legal inquiry.

About Pomerantz LLP

Founded over 85 years ago by Abraham L. Pomerantz, known as a pioneer in securities class action law, the firm is well-regarded for its advocacy on behalf of victims of securities fraud and corporate misconduct. Over the decades, Pomerantz has fought tirelessly for the rights of shareholders and has secured numerous multimillion-dollar damage awards for class members. The firm maintains offices in major cities across the globe, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv.

For further information regarding the lawsuit, individuals can visit Pomerantz’s official site at www.pomerantzlaw.com. Attorney advertising regulations state that prior results in similar cases do not guarantee identical outcomes for new clients.

In light of current developments, Pacira investors should act quickly to assess their legal options following this alarming court ruling affecting the company’s core product. The ramifications of the patent invalidation and the potential impact on Pacira's business practices may continue to unfold, underscoring the importance of staying informed and proactive in this situation.